<DOC>
	<DOCNO>NCT02010645</DOCNO>
	<brief_summary>The goal clinical research study learn eltrombopag give combination decitabine help control advance MDS . The safety study drug combination also study .</brief_summary>
	<brief_title>Eltrombopag With Decitabine Advanced Myelodysplastic Syndrome ( MDS )</brief_title>
	<detailed_description>Study Drug Administration : Each cycle 28 day . If find eligible take part study , receive decitabine vein 1 hour Days 1-5 cycle . You also take eltrombopag capsule mouth 1 time every day cycle . You take empty stomach ( 1 hour meal 2 hour meal ) 8 ounce ( 1 cup ) water . Do eat calcium-rich food ( dairy product juices added calcium ) , take drug ( antacid ) supplement contain iron , calcium , aluminum , magnesium , selenium , and/or zinc 4 hour 4 hour take eltrombopag . If dose eltrombopag vomit , make re-take day . If morning dose miss , may take 5:00 PM day . Study Visits : On Day 1 cycle : - You physical exam . - Blood ( 2-3 teaspoon ) draw routine test . On Days 8 , 15 , 22 Cycle 1 , blood ( 2-3 teaspoon ) draw routine test . If doctor think need , Day 1 Cycles 2-4 , every 3 cycle ( Cycles 7 , 10 , 13 , ) , also bone marrow aspirate/biopsy check status disease cytogenetic testing . If doctor think need , week blood ( 2-3 teaspoon ) draw routine test . End-of-Treatment Visit : Within 5 day last dose study drug , come clinic end-of-treatment visit . The following procedure perform : - You physical exam . - Blood ( 2-3 teaspoon ) draw routine test . - You bone marrow aspirate/biopsy check status disease cytogenetic testing . Length Study : You may continue take study drug long doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up visit . Follow-up Visit : About 28 day last dose study drug , come clinic follow-up visit . The following procedure perform : - You physical exam . - Blood ( 2-3 teaspoon ) draw routine test . This investigational study . Eltrombopag FDA approve commercially available treatment low platelet count patient idiopathic thrombocytopenic purpura ( ITP -- severe bleed disease ) . Decitabine FDA approve treatment MDS commercially available . The combination eltrombopag decitabine treat MDS investigational . Up 50 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Signed , informed consent must obtain prior study specific procedure . 2 . Subjects histologically confirm diagnosis MDS FAB criterion , include MDS RAEBT ( AML 2030 % blast multilineage dysplasia ) chronic myelomonocytic leukemia ( CMML ) least 10 % bone marrow blast World Health Organization ( WHO ) classification eligible . 3 . Advanced MDS virtue intermediate2 highrisk MDS IPSS score , high veryhigh risk IPSSR . 4 . Platelet count &lt; /= 100 x 10^9/L baseline 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 6 . Adequate liver function , evidence serum bilirubin &lt; /= 2x ULN ( except patient confirm diagnosis Gilbert 's Disease ) ALT AST &lt; /= 3x laboratory ULN . 7 . Serum creatinine &lt; /= 2.5x upper limit normal 8 . Subjects must &gt; /= 18 year age time inform consent 9 . Subject practice acceptable method contraception ( documented chart ) . Female subject ( female partner male subject ) must either nonchildbearing potential ( hysterectomy , bilateral oophorectomy , bilateral tubal ligation postmenopausal &gt; 1 year ) , childbearing potential use one follow highly effective method contraception ( i.e . Pearl index &lt; 1.0 % ) 2 week prior administration study medication , throughout study , 28 day completion premature discontinuation study : Complete abstinence intercourse ; Intrauterine device ( IUD ) ; Two form barrier contraception ( diaphragm plus spermicide , male condom plus spermicide ) ; Male partner sterile prior entry study partner female ; Systemic contraceptive ( combine progesterone ) . 1 . Subjects prior exposure thrombopoietinreceptor agonist 2 . Prior hypomethylating agent treatment MDS 3 . Any prior coexisting medical condition investigator 's judgment substantially increase risk associate subject 's participation study 4 . Psychiatric disorder alter mental status preclude understand informed consent process and/or completion necessary study procedure 5 . Active uncontrolled serious infection sepsis study enrollment 6 . Clinically significant gastrointestinal disorder may interfere absorption drug . 7 . History arterial thrombosis ( i.e . stroke ) past year 8 . History venous thrombosis currently require anticoagulation therapy 9 . Unstable angina , congestive heart failure ( New York Heart Association ( NYHA ) &gt; Class II ) , uncontrolled hypertension ( diastolic blood pressure &gt; 100mmHg ) , recent ( within 1 year ) myocardial infarction 10 . Subjects QTc &gt; 480 msec ( QTc &gt; 510 msec subject Bundle Branch Block ) baseline 11 . Pregnant breastfeed 12 . Subjects know history human immunodeficiency virus ( HIV ) active infection hepatitis C virus ( HCV ) hepatitis B virus ( HBV ) , eltrombopag hepatically clear , underlie hepatic impairment may lead increase risk hepatotoxicity . Eltrombopag evaluate combination antiretroviral regimen . 13 . Subjects liver cirrhosis ( determined investigator ) 14 . Subjects hypersensitivity study drug excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Advanced Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>Intermediate-2 Myelodysplastic Syndrome</keyword>
	<keyword>High-Risk Myelodysplastic Syndrome</keyword>
	<keyword>Chronic myelomonocytic leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>Promacta</keyword>
	<keyword>Decitabine</keyword>
	<keyword>Dacogen</keyword>
</DOC>